`
`3/29/04 PHARMAMKT(No Page)
`
` WevvSROOM!
`
`Page 1
`
`3/29/04 Pharma Marketletter (UK) (Pg. Unavail. Online)
`2004 WLNR 21943944
`
`Loaded Date: 01/21/2009
`
`Pharma Marketletter
`
`Copyright 2004 Marketletter Publications Ltd.
`
`March 29, 2004
`
`AstraZeneca's Faslodex meets unmet need in breast cancer.
`
`Faslodex ( fulvestrant), the first new estrogen receptor antagonist since tamoxifen, has finally been launched by
`AstraZeneca in Europe, two years after it has been available in the USA and South America. The product, which
`boasts a unique modeofaction, is now available in Germany, Sweden and Austria and will be rolled out over the next
`year across the whole of the European Union, including the EU accession countries, Iceland and Norway.
`
`The drug acts by binding to estrogen receptors in breast cancer cells and degrading them.It therefore puts a stop to
`tumor estrogen receptor activity, preventing transcription occurring that promotes cell growth. Unlike aromatase
`inhibitors, which prevent the synthesis of estradiol in other body tissues by blocking the aromatase enzyme, Faslodex
`does not reduce the normal amountof circulating estradiol needed to help keep a normallipid profile and healthy
`cardiovascular system, prevent vaginal symptoms, maintain bone mineral density and protect cognitive function.
`
`Faslodex is now licensed for post-menopausal women withestrogen receptor-positive locally-advancedor metastatic
`breast cancer who have experienced disease progression on orafter anti-estrogen therapy. There has been an unmet
`need for an effective endocrine therapy which works in women who have becomeresistant to other hormonal treat-
`ments including tamoxifen and aromatase inhibitors. The potential population for this in Europe is around 120,000
`women.
`
`US medical oncologist John Pippen of Baylor Sammons Cancer Center, Dallas, said the availability of Faslodex for a
`similar indication in the USA has led to rapid uptake among thousands of women. Usually the next step would be
`cytoxic chemotherapy treatment but Faslodex offers another strategy to delay this move and so has proved highly
`popular. There is no cross-resistance between this drug and other hormonal treatments, he said.
`
`Sales so far "beyond expectations"
`
`Uptake has been "beyond expectation," says the company. Global brand director Sarah Holland says Faslodex has
`been AstraZeneca's most successful hormonal cancer treatment at launch in the USA, reaching annual sales of $75
`million by its second year.
`
`© 2015 ThomsonReuters. No Claim to Orig. US Gov. Works.
`
`AstraZeneca Exhibit 2066 p. 1
`InnoPharma Licensing LLC v. AstraZeneca AB IPR2017-00904
`Fresenius-Kabi USA LLC v. AstraZeneca AB IPR2017-01910
`
`
`
`3/29/04 PHARMAMKT(NoPage)
`
`Page 2
`
`Speaking at the European launch during the 4th European Breast Cancer Conference in Hamburg, Germany, John
`Robertson, head of Nottingham University's breast cancer unit in the UK, said the new dmg, administered as a
`once-monthly injection, improves on tamoxifen because, while it also blocks estrogen uptake by breast tumorsit does
`not have tamoxifen's partial estrogenic activity.
`
`The latter is implicated in tamoxifen complications such as endometrial cancer, venous thrombo-embolism and
`stimulation of tumor cells once estrogen receptors start to show resistance following around five years’ therapy.
`Faslodex is a better tolerated treatment than tamoxifen and aromatase inhibitors, causing fewer troublesome side
`effects in the way of hot flushes, joint disorders and vaginal symptoms.
`
`Kurt Possinger, chairman of the Department of Oncology and Hematology, Huboldt University, Berlin, Germany,
`said Faslodex is supported by two large trials comparing it against tamoxifen and aromatase inhibitors. The drug is
`able to shrink breast tumors more than 50%. Compared against the aromatase inhibitor Arimidex (anastrozole), also an
`AstraZeneca drug (see page 20), it has a significantly longer duration of response, Prof Possinger already believesit is
`a better treatment than other endocrine therapies and could be used in preference to aromatase inhibitors after ta-
`moxifen or, eventually, even before tamoxifen. "In my eyesit's the first-line therapy," he concluded.
`
`---- INDEX REFERENCES---
`
`COMPANY: ASTRAZENECA; ASTRAZENECA LTD; ASTRAZENECA SA; ASTRAZENECA PHARMA-
`CEUTICALS LP; ASTRAZENECA (NETHERLANDS ANTILLES); ASTRAZENECA (LATVIA); APTIUM
`ONCOLOGY; ASTRAZENECA (NICARAGUA); ASTRAZENECA PLC
`
`NEWSSUBJECT: (European Union (1EU94); EU News (LEU58): Major Corporations (1MA93); Health & Family
`(1HE30); World Organizations (1IN77))
`
`INDUSTRY: (Healthcare Practice Specialties (1HE49); Internal Medicine (1IN54); Physical Science (1PH15);
`Pharmaceuticals & Biotechnology (1PH13); Science (1SC89); Science & Engineering (1SC33); Oncology & He-
`matology (LON95); Healthcare (1HE06); Cancer Drugs (1CA21))
`
`REGION: (Central Europe (1CE50); North America (1NO39); USA (1US73); Americas (LAM92); Germany
`(1GE16); Europe (1EU83); Western Europe (1WE41))
`
`Language: EN
`
`OTHER INDEXING: (4TH EUROPEAN BREAST CANCER; ASTRAZENECA; BAYLOR SAMMONS CANCER
`CENTER; DEPARTMENT OF ONCOLOGY; EU; EUROPEAN UNION; HEMATOLOGY; HUBOLDT UNI-
`VERSITY; NOTTINGHAM UNIVERSITY; UK; USA) (Faslodex; John Pippen; John Robertson; Kurt Possinger;
`Possinger; Sarah Holland) (United States; United Kingdom)
`
`© 2015 ThomsonReuters. No Claim to Orig. US Gov. Works.
`
`AstraZeneca Exhibit 2066 p. 2
`
`
`
`3/29/04 PHARMAMKT(NoPage)
`
`Page 3
`
`KEYWORDS: (Business, international); (Product introduction); (New Products/Services); (Faslodex (Medication));
`(Faslodex (Medication) - Product introduction); (Product introduction); (Pharmaceutical industry); (Pharmaceutical
`industry - Product introduction)
`
`COMPANY TERMS: ASTRAZENECA PLC
`
`TICKER SYMBOL: AZN
`
`Word Count: 732
`
`3/29/04 PHARMAMKT(NoPage)
`END OF DOCUMENT
`
`© 2015 Thomson Reuters. No Claim to Orig. US Gov. Works.
`
`AstraZeneca Exhibit 2066 p. 3
`
`